HIV-1 Entry and Fusion Inhibitors Market
Number of pages: 100 | Report Format: PDF | Published date: May 12, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
CAGR |
5.5% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Route of Administration, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global HIV-1 entry and fusion inhibitors market is expected to register a revenue CAGR of 5.5% during forecast period.
HIV-1 Entry and Fusion Inhibitors Market Fundamentals
HIV targets the immune system cells in the body. To propagate, the virus must penetrate these cells and replicate itself. Copy after copy is released from these cells and infects additional cells. Treatment with entry inhibitors is one method of preventing viral replication and controlling HIV infection. Entry inhibitors stop HIV from infiltrating healthy body CD4 cells (T-cells). They function differently than many other ARVs, which are active against HIV once it has infected a CD4 cell and include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). Entry inhibitors function by binding to proteins on the surface of CD4 cells or proteins on the surface of HIV. The proteins on HIV's outer coat must bind to the proteins on the surface of CD4 cells in order for HIV to attach to them. Entry inhibitors prevent this. Entry inhibitors are classified into fusion inhibitors, receptor blockers (CCR5 antagonists), and post-attachment inhibitors. Some entrance inhibitors target the surface proteins gp120 and gp41 of HIV. Some entrance inhibitors target the CD4 protein and the CCR5 and CXCR4 receptors on the surface of CD4 cells. Suppose entrance inhibitors are effective in inhibiting these proteins. In that case, HIV will be unable to attach to the surface of CD4 cells and achieve access.
The global HIV-1 entry and fusion inhibitors industry analysis report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the HIV-1 Entry and Fusion Inhibitors market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the HIV-1 entry and fusion inhibitors market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
HIV-1 Entry and Fusion Inhibitors Market Dynamics
The human immunodeficiency virus causes AIDS, one of the most deadly and chronic illnesses. According to the World Health Organization (WHO), about 37.7 million individuals will be infected with the human immunodeficiency virus by 2020. Furthermore, the HIV government estimates that around 1.2 million persons in the United States are infected with HIV. A third of them are ignorant of it and must be tested. In 2019, an estimated 34,800 new HIV infections were recorded in the United States. Following a period of relative stability, the number of new human immunodeficiency virus infections declined by 8%, from 37,800 in 2015 to 34,800 in 2019. In 2019, 36,801 people in the United States and six dependent territories were diagnosed with HIV, a 4% decrease from the previous year.
As individuals become increasingly aware of the infection and its medication treatment options, the number of persons undergoing HIV fusion therapy grows. For instance, 28.2 million HIV patients worldwide were taking antiretroviral medication (ART) in 2020. The number has increased by 1.6 million since 2017. Furthermore, the development of HIV fusion inhibitors and product launches is driving market expansion. Several initiatives are being undertaken by the government /organizations in respective countries and globally to educate and raise awareness, as well as the availability of generic HIV drugs, new drug development, and regulatory approvals for HIV treatment, which are expected to drive the market even further. For instance, ViiV Healthcare, a subsidiary of GlaxoSmithKline, got regulatory clearance from Health Canada in March 2020 for its long-acting regimen for the treatment of HIV: CABENUVA. Additionally, at the National Ryan White Conference on HIV Care and Treatment in August 2022, the U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra announced more than USD 20 million in funding to improve HIV prevention, testing, and treatment services at US health centers. This award will be used by health facilities to expand access to HIV prevention medications.
HIV-1 Entry and Fusion Inhibitors Market Ecosystem
HIV-1 Entry and Fusion Inhibitors Market, by Type
HIV-1 Entry and Fusion Inhibitors Market, by Route of Administration
HIV-1 Entry and Fusion Inhibitors Market by Type
[1236]
The first fusion inhibitor approved by the USFDA was enfuvirtide, a 36-residue peptide generated from gp41. Despite its early effectiveness, Enfuvirtide must be kept at a low temperature, freshly reconstituted, and injected subcutaneously twice daily. Furthermore, injection site responses, quick evolution of resistance viruses, and expensive production costs have hampered its long-term usage.
During the projected period, the worldwide fusion inhibitors segment is predicted to rise due to increased incidence and prevalence of human immunodeficiency virus (HIV) infections or acquired immunodeficiency syndrome (AIDS). Globally, the number of people living with HIV/AIDS has risen dramatically in recent years. During the projection period, the segment is likely to benefit from an increase in the launch of fusion inhibitor medications. Increased R&D activity in HIV fusion inhibitors and viral fusion inhibitors are expected to create a substantial potential for the fusion inhibitors market in the coming years. Manufacturers are concentrating on producing HIV medications.
The market segmentation sections provide the HIV-1 entry and Fusion inhibitors market outlook in terms of the demarcation of different consumer groups. Market segmentation is splitting an industry into subgroups depending on characteristics such as type, route of administration, and region. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data also helps identify potential HIV-1 Entry and Fusion Inhibitors market demand opportunities.
HIV-1 Entry and Fusion Inhibitors Market by Region
The North America region will likely show dominance during the forecast period. North America is one of the strongest regions and contributes significantly to the global HIV entry and Fusion inhibitors market. Patients' increased knowledge of disease-reversing medicines, the establishment of a technologically sophisticated healthcare system, and supporting reimbursement policies are all contributing to the region's rise. In addition, rising government funding and HIV prevention and treatment initiatives are likely to enhance the market throughout the projection period. By example, the US government's spending on the domestic battle against HIV has climbed to more than USD 28 billion per year by fiscal year 2023. This figure includes both discretionary and mandatory spending for Medicare, Medicaid, Social Security, and other mandatory programs. As a result of all the aforementioned variables, the North American region is expected to expand rapidly.
The Asia Pacific market is predicted to develop rapidly during the projected period. This can be attributed to an increase in the region's HIV patient population. The Middle East and Africa market is predicted to develop at a modest rate during the projected period.
Based on the regions, the global HIV-1 entry and fusion inhibitors market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of HIV-1 entry and Fusion inhibitors industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level HIV-1 Entry and Fusion Inhibitors market overview.
Key Components of the Report
HIV-1 Entry and Fusion Inhibitors Market Competitive Landscape
Some of the prominent market players in the global HIV-1 entry and fusion inhibitors market include,
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
HIV-1 Entry and Fusion Inhibitors Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Entry inhibitors function by binding to proteins on the surface of CD4 cells or proteins on the surface of HIV. The proteins on HIV's outer coat must bind to the proteins on the surface of CD4 cells in order for HIV to attach to them.
North America region will have the largest HIV-1 entry and fusion inhibitors market size during the forecast period from 2023 to 2031.
The revenue CAGR in the global HIV-1 entry and fusion inhibitors expected are is expected to be 5.5%.
The rising prevalence of HIV, the development of HIV fusion inhibitors and product launches will create more growth opportunities in the market.
Some restraining factors are responsible for limiting the growth of the market, despite the advancements in research and development, improved scientific understanding of HIV, and the availability of treatment options. There are a lot of HIV-infected or at-risk individuals who do not have access to timely treatment.
The players are continuously involved in new product development, facility expansions, partnerships, and mergers and acquisitions. These are key strategic initiatives that are influencing the industry dynamics.
The rising prevalence, awareness, and several initiatives being undertaken by the government and private organizations are driving the market.
Some of the prominent market players in the global HIV-1 entry and fusion inhibitors market include Genentech, Pfizer, Inc., Theratechnologies Inc.
The fusion Inhibitor (Enfuvirtide) segment has the highest share in the global HIV-1 entry and fusion inhibitors market.
*Insights on financial performance are subject to the availability of information in the public domain